What is/are Liraglutide?
Liraglutide (NN2211), marketed under the brand name Victoza, is a long-acting glucagon-like peptide-1 agonist (GLP-1 agonist) developed by Novo Nordisk for the treatment of type 2 diabetes. The product was approved by the European Medicines Agency (EMA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010.
Liraglutide is marketed under the brandname Victoza in the U.S., India, Canada, Europe and Japan. It has been launched in Germany, Denmark, the Netherlands, the United Kingdom, Ireland, Sweden, Japan, Canada, the United States, France, Malaysia and Singapore. Phase I trials of an oral variant of Victoza (NN9924) started in 2010.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:
- swelling or a lump in your throat area;
- hoarse voice, trouble swallowing, feeling short of breath;
- urinating less than usual or not at all;
- weakness, confusion, increased thirst, loss of appetite, pounding heartbeats or fluttering in your chest;
- swelling, weight gain, feeling short of breath;
- pancreatitis - severe pain in your upper stomach spreading to your back, nausea and vomiting, loss of appetite, fast heart rate; or
- signs of infection such as fever, chills, sore throat, flu symptoms, easy bruising or bleeding (nosebleeds, bleeding gums), mouth sores, unusual weakness.
Less serious side effects may include:
- Headache, dizziness;
- Upset stomach, loss of appetite;
- Nausea, vomiting;
- Diarrhea, constipation;
- Cold symptoms such as stuffy nose, sneezing, sinus pain, sore throat;
- Back pain;
- Tired feeling;
- Mild skin rash; or
- Redness or rash where the medicine was injected.
This article uses material from the Wikipedia article Liraglutide, which is released under the Creative Commons Attribution-Share-Alike License 3.0.